Rita A. Mukhtar

Aug 9, 2024 | onclive.com | Rita A. Mukhtar

CommentaryVideoAugust 9, 2024Author(s):Rita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma. Rita Mukhtar, MD, breast oncologic surgeon, associate professor of surgery, Division of Surgical Oncology, Invasive lobular Carcinoma Program, University of California, San Francisco, discusses the risk of disease recurrence in patients with invasive lobular carcinoma compared with those with invasive ductal carcinoma.

Jul 20, 2024 | onclive.com | Rita A. Mukhtar

CommentaryVideoJuly 20, 2024Author(s):Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma. Rita Mukhtar, MD, breast oncologic surgeon, associate professor of surgery, Division of Surgical Oncology, Lobular Breast Cancer Program, University of California, San Francisco, discusses challenges in the diagnosis and locoregional management of invasive lobular carcinoma.

Jul 19, 2024 | nature.com | Steffi Oesterreich |Adrian Lee |Fangyuan Chen |Rachel C. Jankowitz |Rita A. Mukhtar |Matthew J Sikora | +3 more

AbstractThere is growing awareness of the unique etiology, biology, and clinical presentation of invasive lobular breast cancer (ILC), but additional research is needed to ensure translation of findings into management and treatment guidelines. We conducted a survey with input from breast cancer physicians, laboratory-based researchers, and patients to analyze the current understanding of ILC, and identify consensus research questions.

Jun 14, 2023 | jamanetwork.com | Rita A. Mukhtar |Christina Yau |Laura Esserman

In Reply We thank O’Keefe and Wallace for reading our study.1 In our analysis of data from I-SPY2, a prospective, randomized, neoadjuvant trial with prespecified pathological assessment of specimens according to the Residual Cancer Burden method, we found a nonsignificant difference in 3-year event-free survival (EFS) and distant recurrence-free survival (DRFS) among those with pathologic complete response (pCR) with or without residual ductal carcinoma in situ (DCIS).